The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease

The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease

Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is not recommended. We present the complexities...

Full description

Saved in:
Bibliographic Details
Main Authors: Claire Y Mou, Daniel J Henderson, Angela G Matson, Karen M Herd, David W Reid, Timothy Riddles, Ellie Johnson, Brett McWhinney, Rebecca Swenson, Andrew Burke, Ieuan E S Evans
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:European Clinical Respiratory Journal
Subjects:
Therapeutic drug monitoring
Cystic Fibrosis
Trikafta
Kaftrio
non-tuberculous mycobacteria
elexacaftor/tezacaftor/ivacaftor
Online Access:https://www.tandfonline.com/doi/10.1080/20018525.2025.2458341
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/20018525.2025.2458341

Similar Items